Lupus Canada and Lupus Foundation of America Award Research Grant Aiming to Reduce Shingles Risk for People with Lupus

Lupus Canada, in collaboration with the Lupus Foundation of America, is thrilled to announce that Dr. Arielle Mendel has been awarded the 2024 Lupus Canada Catalyst Award for her study on the safety and efficacy of the shingles vaccine for people with systemic lupus erythematosus (SLE).

Shingles, caused by the reactivation of the varicella (chickenpox) virus, is a painful and potentially severe condition. People with lupus are up to five times more likely to develop shingles at a younger age due to altered immune function and immunosuppressive treatments. 

Dr. Mendel’s research will investigate which SLE patients receive the shingles vaccine, its association with lupus flares, and the immune response in people with lupus.

“Prevention is crucial as shingles can present more severely in people with lupus. This study aims to provide critical insights into the shingles vaccine and alleviate patient concerns about vaccine-related lupus flares,” says Dr. Mendel.

The Lupus Canada Catalyst Award supports innovative research to improve the quality of life for people with lupus.

“Partnering with Lupus Canada allows us to fund vital areas of lupus research that need more attention,” says Joy Buie, PhD, MSCR, RN, Vice President of Research, Lupus Foundation of America.

“This partnership helps channel efforts into essential lupus research,” adds Thomas J. Simpson, Chair of Lupus Canada. “Dr. Mendel’s study has the potential to fill a crucial gap in lupus research and help people with lupus protect themselves better.”